Drug General Information |
Drug ID |
D0O0QN
|
Former ID |
DNC006140
|
Drug Name |
3-aminoacetamido-4'-methylfuro[3,2-g]coumarin
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C14H12N2O4
|
Canonical SMILES |
CC1=COC2=C1C=C3C=C(C(=O)OC3=C2)NC(=O)CN
|
InChI |
1S/C14H12N2O4/c1-7-6-19-12-4-11-8(2-9(7)12)3-10(14(18)20-11)16-13(17)5-15/h2-4,6H,5,15H2,1H3,(H,16,17)
|
InChIKey |
MNKUYMIFZBIEPU-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Amine oxidase [flavin-containing] A |
Target Info |
Inhibitor |
[1]
|
BioCyc Pathway
|
Superpathway of tryptophan utilization
|
Dopamine degradation
|
Putrescine degradation III
|
Noradrenaline and adrenaline degradation
|
Serotonin degradation
|
Superpathway of melatonin degradation
|
Melatonin degradation II
|
KEGG Pathway
|
Glycine, serine and threonine metabolism
|
Arginine and proline metabolism
|
Histidine metabolism
|
Tyrosine metabolism
|
Phenylalanine metabolism
|
Tryptophan metabolism
|
Drug metabolism - cytochrome P450
|
Metabolic pathways
|
Serotonergic synapse
|
Dopaminergic synapse
|
Cocaine addiction
|
Amphetamine addiction
|
Alcoholism
|
NetPath Pathway
|
IL4 Signaling Pathway
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesis
|
5-Hydroxytryptamine degredation
|
Dopamine receptor mediated signaling pathway
|
PathWhiz Pathway
|
Histidine Metabolism
|
Tyrosine Metabolism
|
Glycine and Serine Metabolism
|
Reactome
|
Norepinephrine Neurotransmitter Release Cycle
|
WikiPathways
|
SIDS Susceptibility Pathways
|
Biogenic Amine Synthesis
|
Oxidative Stress
|
Dopamine metabolism
|
Phase 1 - Functionalization of compounds
|
Neurotransmitter Release Cycle
|
Neurotransmitter Clearance In The Synaptic Cleft
|
Serotonin Transporter Activity
|
References |
REF 1 | J Med Chem. 2006 Feb 9;49(3):1149-56.A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. |